*All Times Shown in PST

7:00 am Registration & Morning Coffee Networking

7:20 am Chair’s Opening Remarks

  • Angus Sinclair Senior Vice President ImmunoOncology, IGM Biosciences

Bridging the Gap Between Pre-Clinical Tumor Models & Translational Research in IO

7:30 am Use of Human Knock-in Mice for Selecting New Generation of Immune Checkpoint Inhibitors


• How to select the best human knock-in mouse model for a specific project
• Tumor models and analysis of the immunological response in human knock-in mice
• Can human knock-in mice be used for PK analysis?

8:00 am Evaluation of Safety & Efficacy of Bispecific & CAR T Therapies in Humanized Mice

  • Jiwon Yang In Vivo Senior Scientist Product Development, The Jackson Laboratory


  • Novel in vivo model for cytokine release syndrome to de-risk antibody and cellular therapies for pre-clinical development
  • Evaluate drug effects on individual PBMC donors
  • Determine drug dose-response with efficacy and safety

8:30 am Understanding Toxicity in IO & Utilizing This to Create A Bigger Therapeutic Window

  • Yufei Wang Research Fellow, Department of Cancer Immunology & Virology, Dana-Farber Cancer Institute Harvard Medical School


• Understanding the implications of the similarities between tumors and our own immune system: are we doomed to experience toxicity?
• Targeting the weakest points in a patient’s cancer to counteract the problems of toxicity
• Maximizing your therapeutic window: having tumors of the right size and dosing of drugs
• Dealing with off-target effects and how this can affect your mode

9:00 am Panel Discussion: Generating Meaningful Data with Your IO Models


In this panel discussion, we will
• Discuss how to make agents that work perfectly in-vitro translate into a better drug in the clinic
• Explore gold standards and benchmarking what good indications are for translatability in the clinic
• Assess what good looks like for our tumor models

9:30 am Virtual Speed Networking and Morning Break


Grab a morning coffee and enjoy this structured networking break to reconnect with fellow industry and academic experts.

10:30 am Humanized Models Enabling Enhanced Clinical Relevancy & Translatability

  • Kader Thiam Senior Vice President – Discovery, Preclinical Models & Services, genOway


• Immune checkpoint humanized mouse models: assessment of biologics efficacy and combo-therapy; importance of model design on overall model performances
• BRGSF-HIS hCD34+ reconstituted mice featuring human lymphoid and myeloid compartments: analysis of the human immune system and effector function

11:00 am Predicting the Safety & Efficacy of Mouse Models


• Clarifying the differences between surrogate antibodies and your clinical candidate
• PKPD: understanding it’s importance and relevance in IO treatment
• Establishing how to determine dosing frequency and volume from your mouse models
• Measuring efficacy: determining mechanistic measures including surrogate endpoints in efficacy studies

11:30 am Careful Use of Your Pre-Clinical Mouse Models for Translatability

  • Sanjay Khare SVP, Head Immuno-Oncology, Coherus Biosciencies


Too many failures on mouse model directed clinical experiments – how to overcome this
• Exploring the importance of understanding human correlate of mouse biology
• MOA based translation – not just efficacy
• Evaluating that human immune/tumor models have limited value in understanding the biology

12:00 pm Networking Lunch

1:15 pm Influence of the Gut Microbiome Toward Preclinical Translation of Cancer Immunotherapy

  • Hans Layman Senior Director, Translational Medicine, Federation Bio


• Key species of bacteria exist that influence preclinical efficacy in tumor models
• Pre-treatment regimens, such as antibiotics, need to be considered in most preclinical models as these can impact the endogenous microbiome and may impact clinical efficacy
• Not all microbiomes are created equal and the depth at which we sequence (16S, metagenomic, etc) is critical to align on to speak the same language across microbiome studies for biomarkers and possible treatment modalities

1:45 pm Outlining Pros & Cons of Slower Growing Models That More Accurately Represent Human Tumor Growth Kinetics


• Slowing it down: what are the impacts of comparing human and mouse tumors that grow at different rates?
• Developing representative models that including slower growing models to resemble more closely what is going on in the human tumor
• Understanding the challenge of monitoring growth of tumors that develop at different rates

2:15 pm Immuno-oncology on a Chip: Vascularized Micro-Tumors for Testing Cellular & Molecular Immunotherapeutics

2:30 pm Persistence and Anti-Tumor Efficacy of Allogeneic CAR-NK Cells in Humanized IL15 Mice

  • Kelly Lee Senior Staff Scientist, Pre-Clinical Lead, Senti Biosciences


• Exploring NK cell persistence in JAX vs Taconic IL15 mice
• What is the persistence of NK cells from different NK donors?
• Delving into the anti-tumor efficacy of CAR-NK cells in vivo

Creating Predictive Models for Tumor Heterogeneity

3:00 pm Organ On Chip: Facing the Complications of Intra & Inter-Tumor Heterogeneity

  • Zhao Chen Senior Principal Scientist, Novartis Institutes for BioMedical Research (NIBR)


• Establishing better models for IO using organ on a chip
• Understanding the importance of the dynamic TME in primary and acquired cross-resistance

3:30 pm Chair’s Closing Remarks, End of Day One